Latigo Biotherapeutics, Inc.: AI Biotechnology LLC amends Schedule 13G stake filing

AI Biotechnology LLC filed an amended Schedule 13G with the SEC (accession 0001193125-26-452089) disclosing a revised beneficial ownership position in Latigo Biotherapeutics, Inc. The amendment updates the investor's previously reported stake in the clinical-stage biotech, though the filing did not specify a change in share count or percentage in the headline disclosure. Schedule 13G filings are required of passive investors holding more than 5% of a company's voting securities, so the amendment signals a shift in AI Biotechnology's position size or reporting status. The move matters because concentrated institutional ownership can influence Latigo's shareholder base and governance ahead of key clinical and financing milestones. Investors will watch for the detailed ownership figures in the filing and any subsequent 13G or 13D amendments that clarify whether AI Biotechnology is accumulating or trimming its stake.